» Articles » PMID: 7517705

Autoantibodies to IGF-1 Binding Sites in Thyroid Associated Ophthalmopathy

Overview
Journal Autoimmunity
Date 1993 Jan 1
PMID 7517705
Citations 60
Authors
Affiliations
Soon will be listed here.
Abstract

Graves' disease is an autoimmune disorder but the nature of the association between hyperthyroidism and ophthalmopathy is not yet understood. Serum autoantibodies to orbital tissues have previously been identified and the cross-reactivity with orbital and thyroid antigens has been implicated in the development of thyroid-associated ophthalmopathy (TAO). The ophthalmopathy of Graves' disease is remarkable for the hypertrophy of extraocular muscles and proliferation of fibroblasts within the orbit; features which suggest a possible involvement of growth factors. The present study was therefore undertaken to investigate the interaction of IgGs extracted from the sera of patients with Graves' disease, with or without overt ophthalmopathy, with respect to IGF-1 receptor binding sites on fibroblasts from human orbital tissue. IGF-1 binding sites were demonstrated on human orbital fibroblast monolayers grown from eye muscle explants. These cells exhibited a population of high affinity IGF-1 binding sites (Kd, 0.5nM SEM +/- 0.05). IgG prepared from sera taken from patients with Graves' disease (n = 23) significantly inhibited [125I]IGF-1 binding to orbital fibroblasts when compared to IgGs prepared from normal volunteers (n = 13, p < 0.002). It was found that 12 of 23 (52%) patients' IgG samples gave rise to significant levels of inhibition of [125I]IGF-1 binding to orbital fibroblasts. The IgG preparations did not bind directly to IGF-1. This study demonstrates that IgG prepared from patients with Graves' disease with or without overt ophthalmopathy interact with IGF-1 binding sites on orbital fibroblasts whereas IgG from normal subjects had no significant effect.(ABSTRACT TRUNCATED AT 250 WORDS)

Citing Articles

Transcriptomic profiling of thyroid eye disease orbital fat demonstrates differences in adipogenicity and IGF-1R pathway.

Kim D, Kim S, Han J, Belday K, Li E, Mahoney N JCI Insight. 2024; 9(24).

PMID: 39704170 PMC: 11665563. DOI: 10.1172/jci.insight.182352.


Advances of IGF-1R inhibitors in Graves' ophthalmopathy.

Wang M, Liu L Int Ophthalmol. 2024; 44(1):435.

PMID: 39578269 DOI: 10.1007/s10792-024-03358-5.


A Comprehensive Review of Thyroid Eye Disease Pathogenesis: From Immune Dysregulations to Novel Diagnostic and Therapeutic Approaches.

Kulbay M, Tanya S, Tuli N, Dahoud J, Dahoud A, Alsaleh F Int J Mol Sci. 2024; 25(21).

PMID: 39519180 PMC: 11546489. DOI: 10.3390/ijms252111628.


Mouse model of Graves' orbitopathy induced by the immunization with TSHR A and IGF-1R α subunit gene.

Wu R, Li N, Wang X, Wang S, Tan J, Wang R J Endocrinol Invest. 2024; 47(10):2507-2519.

PMID: 38662129 DOI: 10.1007/s40618-024-02344-z.


Teprotumumab in thyroid eye disease.

Goldberg H, Malik A Saudi J Ophthalmol. 2024; 38(1):29-33.

PMID: 38628412 PMC: 11017013. DOI: 10.4103/sjopt.sjopt_179_23.